Metagenomi, Inc. Common Stock (MGX)vsRevolution Medicines Inc (RVMD)
MGX
Metagenomi, Inc. Common Stock
$1.16
0.00%
HEALTHCARE · Cap: $43.82M
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Metagenomi, Inc. Common Stock generates 1728% more annual revenue ($13.56M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. MGX earns a higher WallStSmart Score of 39/100 (F).
MGX
Hold39
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 11196.0%
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MGX
The strongest argument for MGX centers on Price/Book, Operating Margin.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : MGX
The primary concerns for MGX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
MGX is growing revenue faster at -69.8% — sustainability is the question.
MGX generates stronger free cash flow (-20M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MGX scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Metagenomi, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?